• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Vascular Biogenics Ltd.

    10/17/23 8:00:16 AM ET
    $VBLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VBLT alert in real time by email
    Inline XBRL Viewer
    • Menu Menu
      Information Save XBRL Instance Save XBRL Zip File Open as HTML Settings Help
    • Sections Sections
    • Reference Options
    • Data Data
    • Tags Tags
    • More Filters More Filters
      Periods
      Measures
      Axis
      Members
      Scale
      Balance 2
    • Reset All Filters
    • Links
    • Facts

    Loading Inline Form.

    Tagged Sections

    Help

    The Inline XBRL viewer allows a user to quickly and easily review details of the tagged information in an Inline document by automatically placing a top and bottom highlight border around each tagged numeric fact and left and right border for each block tagged fact. Hovering over a tagged fact will highlight (shade) all content related to the tagged fact, and clicking on a tagged fact will reveal its tagging details in the Fact Review Window. Navigation, search and filter options are also provided to easily refine and identify specific types of tagged information.

    The Fact Review Window shows the tagging details for the currently selected fact, which is highlighted with a solid blue border. There are four categories of fact detail which can be viewed; an "N/A" value indicates there is no available information for the item within the given category:

    • Attributes - All primary information (as applicable) describing the tagged fact including period, sign, decimals, dimensional detail (axes and members), scale, measure and data type.
    • Labels - Detailed documentation (definition) for the tag used, and other labels.
    • References - Authoritative reference information (as applicable) for the selected tag.
    • Calculation - Balance and calculation hierarchy details (numeric non-dimensioned items only).

    There are two ways to search the document: FACTS AND SECTIONS. To search information, enter a keyword in a search box and select the magnifying glass icon to return matching results. Search operators "and" (via "AND" or "&") and "or" (via "OR" or "|") are available to further refine a search.

    FACTS

    The Search Facts box can be used to find tagged facts matching entered keywords. By default, tag name, tag labels, and tagged content are included in Search. Tagged facts matching the search criteria are shown with a yellow-colored (default) shading on the page and appear in the Facts List. Select the "X" button to the left of the magnifying glass icon to clear the search.

    The content included in Search can be increased to included tag definitions, dimensions, and authoritative references by selecting the cog / wheel icon to the left of the search box. See Settings for more information.

    SECTIONS

    The Search Sections box can be used to filter the tagged sections of the financial statements.

    Filters change the number of highlighted facts and items in the fact list by providing several ways to review and pinpoint certain tagged information. Multiple filters can be used at once.

    DATA FILTERS

    These filter options allow the user to refine the highlighted tagged facts by data type:

    • All - Displays all tagged data (default)
    • Amounts Only - Numeric facts only
    • Text Only - Textual facts only
    • Calculations Only - Numeric facts participating in a calculation only
    • Negatives Only - Negative Numeric amounts only
    • Additional Items Only - Tagged facts without a corresponding HTML presentation (i.e., hidden facts) only

    TAGS FILTER

    These filters allow the user to refine the highlighted facts by tag type:

    • All - Displays all tagged data (default)
    • Standard Only- Facts with standard tags from a common taxonomy (e.g., US_GAAP, IFRS, DEI).
    • Custom Only - Facts with extension "custom" tags unique to the entity's document.

    MORE FILTERS

    Additional filters that allow user to further refine the highlighted facts:

    • Periods - List of all used context years and reporting periods
    • Measures - List of all used units of measure (e.g., US Dollars); as applicable
    • Axis - List of all used axis (dimensions); as applicable (dimensions); as applicable
    • Scale - List of all used scaled options (e.g., thousands, millions); as applicable
    • Balance - Debit, credit; as applicable

    Multiple filters work in conjunction with each other. For example, selecting the "Amounts Only" Data filter and "Custom Only" Tags filter will highlight only numeric tagged facts using custom tags and list them in the fact list. Active filters are displayed in the Filter toolbar as they are selected. Active filters can be removed individually by unchecking or selecting ALL option for each filter, or all at once via the "Reset All Filters" option.

    On the toolbar, select the "count" to the right of the word Facts (e.g., Facts 234) to reveal the Facts List results - a navigable listing of all currently highlighted tagged facts. The count represents the current number of facts.

    By default, all tagged facts are displayed in the Fact List Results. The list content and count reflects the currently highlighted facts (i.e., both Filters and Search criteria refine the list to match the highlighted tagged facts). Navigation controls are available to move through the list as well as move the current view to the corresponding highlighted fact location automatically. When a fact in the Facts Results List is selected, it will reveal the Fact Review Window.

    Certain letters may appear to the right of an item in the Fact Result list to indicate a certain property. If the letter "A" appears for a fact, it indicates the fact is additional data (i.e., hidden with potentially no corresponding HTML presentation). If the letter "C" appears, the fact is tagged with a custom tag. If the letter "D" appears, the fact is tagged with dimensional information.

    The SECTIONS toolbar item provides a listing of the tagged sections of the Inline document. Sections are divided into three groups:

    • Document & Entity Information
    • Financial Statements
    • Notes to the Financial Statements

    By expanding a group and selecting a section item in the listing, Inline XBRL viewer will navigate to that section. When the Tagged Sections feature is open, the Search Sections box will additionally filter the list of sections to only those sections that match the entered criteria.

    Information

    The Information menu item provides additional detail about the current Inline document and customizable viewer settings.

    • Company and Document - Basic company and document information
    • Tags - Fact and tag (standard and custom) information
    • Files - Files used
    • Additional Items - Additional hidden data that's been tagged but potentially does not have a corresponding location in the HTML

    Save XBRL Instance

    The Save XBRL Instance menu item allows an XBRL instance document (*.xml) that is extracted from the Inline document to be saved locally for use by software supporting the XBRL format.

    Save XBRL Zip

    The Save XBRL Zip menu item allows a zip file (*.zip) that contains the as-provided XBRL instance document and related custom taxonomy files to be saved locally.

    Settings

    The Settings menu item provides the ability to customize Viewer features.

    Tagged Fact Hover

    • On - Displays the hover fact review window for any tagged fact*
    • Off - Hides the hover fact review window for any tagged fact (default)

    * May impact performance with certain web browsers.

    Auto Scrolling Position (This setting will have no effect on IE 10 or Safari)

    • Top - Selecting a fact from the Sections Menu or the Fact Menu will automatically scroll that element to the Top of the Inline XBRL viewer window (default)
    • Center - Selecting a fact from the Sections Menu or the Fact Menu will automatically scroll that element to the middle of the Inline XBRL viewer window

    Highlight Colors (Use the save and reset buttons to save the selected setting or reset to default)

    • Tagged Data - Change the highlight color of the tagged fact border
    • Search Results - Change the background color of tagged items matching the Search results
    • Selected Fact - Change the color of highlight border used to identify the currently selected fact
    • Tag Shading (hover) - Change the color of the shading applied to tagged data on hover

    Search Options

    • Match Case - Matches the specific case of the entered Search keyword
    • Include Labels - Extends Search to include tag labels
    • Include Definitions - Extends Search to include tag definitions
    • Include Dimensions - Extends Search to include dimensional detail
    • Include References - Extends Search to include authoritative reference information. Optionally specify the reference parts to include in the search (e.g., topic, subtopic, section)

    Help(this content)

    Version

    Indicates the current build of the Inline XBRL viewer application.

    Facts

    Settings

    Selecting a fact from the Sections Menu or the Fact Menu will automatically scroll that element to the (Top, or Middle) of the viewer window. This setting will have no use on IE 10, or Safari.





    Nested Facts /

    Get the next $VBLT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VBLT

    DatePrice TargetRatingAnalyst
    7/20/2022Outperform → Perform
    Oppenheimer
    7/20/2022Buy → Neutral
    H.C. Wainwright
    7/18/2022$5.50Outperform
    Oppenheimer
    4/28/2022$5.00Buy
    Chardan Capital Markets
    More analyst ratings

    $VBLT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Vascular Biogenics Ltd. (Amendment)

      SC 13G/A - Notable Labs, Ltd. (0001603207) (Subject)

      1/11/24 5:22:04 PM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Vascular Biogenics Ltd.

      SC 13D - Notable Labs, Ltd. (0001603207) (Subject)

      10/19/23 1:34:02 PM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Vascular Biogenics Ltd.

      SC 13G - Vascular Biogenics Ltd. (0001603207) (Subject)

      2/1/22 4:20:25 PM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VBLT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Vascular Biogenics downgraded by Oppenheimer

      Oppenheimer downgraded Vascular Biogenics from Outperform to Perform

      7/20/22 9:01:50 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vascular Biogenics downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Vascular Biogenics from Buy to Neutral

      7/20/22 7:39:29 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer resumed coverage on Vascular Biogenics with a new price target

      Oppenheimer resumed coverage of Vascular Biogenics with a rating of Outperform and set a new price target of $5.50

      7/18/22 9:22:46 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VBLT
    SEC Filings

    See more
    • SEC Form DEF 14A filed by Vascular Biogenics Ltd.

      DEF 14A - Notable Labs, Ltd. (0001603207) (Filer)

      2/16/24 9:00:13 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Vascular Biogenics Ltd.

      PRE 14A - Notable Labs, Ltd. (0001603207) (Filer)

      2/5/24 5:00:08 PM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vascular Biogenics Ltd. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K - Notable Labs, Ltd. (0001603207) (Filer)

      2/2/24 4:05:36 PM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VBLT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Feinberg Peter

      4 - Notable Labs, Ltd. (0001603207) (Issuer)

      1/26/24 11:05:45 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Patsi Tuomo

      4 - Notable Labs, Ltd. (0001603207) (Issuer)

      1/26/24 11:05:20 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Galen Michele

      4 - Notable Labs, Ltd. (0001603207) (Issuer)

      1/26/24 11:04:43 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VBLT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Notable Labs Closes Merger Transaction With VBL Therapeutics

      - Notable expects to initiate trading on the Nasdaq Capital Market under ticker symbol "NTBL" effective at market open on October 17 - - Aggregate net transaction proceeds expected to fund planned operations into 2025 - - Completed previously announced $10.3 million private placement with leading healthtech-focused investors, led by Builders VC, B Capital Group, Y Combinator, First Round Capital, and Founders Fund - - Predictive Precision Medicines Platform ("PPMP") applied to select and develop two clinical-stage therapeutic candidates with lead programs in acute myeloid leukemia ("AML"); four Phase 2 milestones expected by 1Q 2025 including Phase 2a results for lead asset Volasertib in

      10/16/23 1:01:41 PM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VBL Therapeutics Announces Results of Annual and Special Shareholder Meeting

      Approved Merger with Notable Labs and All Other Proposals Merger Expected to Close and Begin Trading as Combined Company Under the NTBL Ticker on Nasdaq Next Week, Subject to Effectiveness of Approved Israeli Corporate Actions MODI'IN, Israel and NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) ("VBL"), today announced that its shareholders voted to approve the previously announced proposed merger (the "Merger") with Notable Labs, Inc. ("Notable"), at the annual and special meeting (the "Meeting") which took place today, October 12, 2023. Over 98% of the votes cast at the Meeting were cast in favor of the approval of the Merger. VBL's shareholders also voted t

      10/12/23 9:00:00 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder Meeting

      MODI'IN, Israel and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) ("VBL"), reminds its shareholders to vote in favor of the previously announced proposed merger (the "Merger") with Notable Labs ("Notable") at the annual and special meeting (the "Meeting") for shareholders of record as of September 5, 2023. All VBL shareholders, regardless of number of ordinary shares, nominal value of NIS 0.01 ("VBL Ordinary Shares") held, are encouraged to vote "FOR" the Merger and related proposals described in the definitive proxy statement/prospectus/information statement previously filed by VBL with the U.S. Securities and Exchange Commission (the "SEC") in connection with

      10/4/23 8:00:00 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VBLT
    Leadership Updates

    Live Leadership Updates

    See more

    $VBLT
    Financials

    Live finance-specific insights

    See more
    • Alpha Tau Medical Ltd. Appoints Ruth Alon to its Board of Directors

      JERUSALEM, March 21, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (NASDAQ:DRTS), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced the appointment of Ms. Ruth (Ruti) Alon to its Board of Directors, effective immediately. "We are pleased to welcome Ruti as the newest member of our Board of Directors," said Uzi Sofer, Chief Executive Officer and Chairman of Alpha Tau. "Ruti's extensive knowledge and experience advising healthcare companies through financial and strategic operations will be a tremendous asset to the Company. We are eager to have her on board and benefit from her insights into our corporate and clinical plan as we grow the Company." Ruti

      3/21/22 4:05:00 PM ET
      $DRTS
      $MACA
      $VBLT
      Medical/Dental Instruments
      Health Care
      Blank Checks
      Finance
    • VBL Therapeutics Announces Appointment of Matthew Trudeau as Chief Commercial Officer

      CCO appointment positions VBL to advance and accelerate commercialization strategy for ofra-vec (VB-111) Enrollment in the OVAL Study, a 400 patient Phase 3 registration-enabling trial in ovarian cancer, expected to be completed this quarter; PFS co-primary endpoint readout expected in 2H22 has potential to support BLA filing TEL AVIV, Israel and NEW YORK, Jan. 18, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced the appointment of Matthew Trudeau to the newly created position of Chief Comm

      1/18/22 8:00:00 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VBL Therapeutics Announces Appointment of Sam Backenroth as Chief Financial Officer and Establishes Operations in the United States

      TEL AVIV, Israel and NEW YORK, Oct. 05, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) today announced the appointment of Sam Backenroth as chief financial officer (CFO) effective immediately. Mr. Backenroth is an accomplished corporate finance veteran with demonstrated success in building and financing private and public biotechnology companies. In connection with the appointment, VBL established U.S. operations in New York, which will be managed by Mr. Backenroth, and he will be responsible for leading the company's future financing and business development activities to support the company's growth initiatives. Mr. Backenroth succeeds Mr. Amos Ron, who is retiring but will cont

      10/5/21 8:00:00 AM ET
      $NBSE
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Notable Labs Closes Merger Transaction With VBL Therapeutics

      - Notable expects to initiate trading on the Nasdaq Capital Market under ticker symbol "NTBL" effective at market open on October 17 - - Aggregate net transaction proceeds expected to fund planned operations into 2025 - - Completed previously announced $10.3 million private placement with leading healthtech-focused investors, led by Builders VC, B Capital Group, Y Combinator, First Round Capital, and Founders Fund - - Predictive Precision Medicines Platform ("PPMP") applied to select and develop two clinical-stage therapeutic candidates with lead programs in acute myeloid leukemia ("AML"); four Phase 2 milestones expected by 1Q 2025 including Phase 2a results for lead asset Volasertib in

      10/16/23 1:01:41 PM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VBL Therapeutics and Notable Labs Announce Definitive Merger Agreement

      Merger will create Nasdaq-listed, clinical-stage therapeutic platform company developing new precision medicines for patient populations selected through Notable's proprietary Predictive Precision Medicines Platform ("PPMP") Notable's validated PPMP combines multi-dimensional biological assays and machine learning to bio-simulate a patient's cancer treatment and predict their clinical response to the actual treatment Notable has applied its PPMP to selecting and developing two clinical-stage therapeutic candidates in acute myeloid leukemia ("AML"); Phase 2a results for lead asset Volasertib in adult AML in platform-predicted responding patients expected in 3Q 2024 Leading healthtech-focus

      2/23/23 7:00:00 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VBL Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

      OVAL Phase 3 top-line data expected in 2H 2022; with positive results, VBL anticipates submitting a BLA to the FDA in 1H 2023 Conference Call and Webcast at 8:30 a.m. ET Today TEL AVIV, Israel and NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) (VBL), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced financial results for the first quarter ended March 31, 2022, and provided a corporate update. "We continue to execute on our development and strategic objectives, which we believe have positioned us for a potentia

      5/17/22 7:00:00 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care